CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Quarterly Assets in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
Summary
Charles River Laboratories International, Inc. quarterly Assets history and growth rate from Q2 2010 to Q3 2024.
  • Charles River Laboratories International, Inc. Assets for the quarter ending September 28, 2024 was $8B, a 5.22% increase year-over-year.
Assets, Quarterly (USD)
Assets, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $8B +$397M +5.22% Sep 28, 2024 10-Q 2024-11-06
Q2 2024 $7.95B +$176M +2.26% Jun 29, 2024 10-Q 2024-08-07
Q1 2024 $8.15B +$453M +5.89% Mar 30, 2024 10-Q 2024-05-09
Q4 2023 $8.2B +$592M +7.79% Dec 30, 2023 10-Q 2024-11-06
Q3 2023 $7.61B +$224M +3.04% Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $7.77B +$243M +3.23% Jul 1, 2023 10-Q 2023-08-09
Q1 2023 $7.7B +$624M +8.83% Apr 1, 2023 10-Q 2023-05-11
Q4 2022 $7.6B +$578M +8.24% Dec 31, 2022 10-K 2024-02-14
Q3 2022 $7.38B +$324M +4.6% Sep 24, 2022 10-Q 2022-11-02
Q2 2022 $7.53B +$809M +12% Jun 25, 2022 10-Q 2022-08-03
Q1 2022 $7.08B +$1.27B +21.8% Mar 26, 2022 10-Q 2022-05-04
Q4 2021 $7.02B +$1.53B +27.9% Dec 25, 2021 10-K 2023-02-22
Q3 2021 $7.06B +$1.85B +35.4% Sep 25, 2021 10-Q 2021-11-03
Q2 2021 $6.72B +$1.48B +28.2% Jun 26, 2021 10-Q 2021-08-04
Q1 2021 $5.81B +$607M +11.7% Mar 27, 2021 10-Q 2021-05-04
Q4 2020 $5.49B +$798M +17% Dec 26, 2020 10-K 2022-02-16
Q3 2020 $5.21B +$631M +13.8% Sep 26, 2020 10-Q 2020-11-09
Q2 2020 $5.24B +$615M +13.3% Jun 27, 2020 10-Q 2020-08-05
Q1 2020 $5.2B +$1.28B +32.5% Mar 28, 2020 10-Q 2020-05-07
Q4 2019 $4.69B +$837M +21.7% Dec 28, 2019 10-K 2021-02-17
Q3 2019 $4.58B +$786M +20.7% Sep 28, 2019 10-Q 2019-11-06
Q2 2019 $4.63B +$760M +19.6% Jun 29, 2019 10-Q 2019-07-31
Q1 2019 $3.93B +$926M +30.8% Mar 30, 2019 10-Q 2019-05-07
Q4 2018 $3.86B +$926M +31.6% Dec 29, 2018 10-K 2020-02-11
Q3 2018 $3.8B +$931M +32.5% Sep 29, 2018 10-Q 2018-11-07
Q2 2018 $3.87B +$1.09B +39.4% Jun 30, 2018 10-Q 2018-08-08
Q1 2018 $3B +$304M +11.3% Mar 31, 2018 10-Q 2018-05-10
Q4 2017 $2.93B +$218M +8.04% Dec 30, 2017 10-K 2019-02-13
Q3 2017 $2.87B +$176M +6.53% Sep 30, 2017 10-Q 2017-11-09
Q2 2017 $2.77B +$10.7M +0.39% Jul 1, 2017 10-Q 2017-08-09
Q1 2017 $2.7B +$593M +28.2% Apr 1, 2017 10-Q 2017-05-10
Q4 2016 $2.71B +$643M +31.1% Dec 31, 2016 10-K 2018-02-13
Q3 2016 $2.69B +$657M +32.3% Sep 24, 2016 10-Q 2016-11-02
Q2 2016 $2.76B +$877M +46.5% Jun 25, 2016 10-Q 2016-08-03
Q1 2016 $2.1B +$256M +13.9% Mar 26, 2016 10-Q 2016-05-04
Q4 2015 $2.07B +$198M +10.6% Dec 26, 2015 10-K 2017-02-14
Q3 2015 $2.03B +$190M +10.3% Sep 26, 2015 10-Q 2015-11-04
Q2 2015 $1.89B +$22.5M +1.21% Jun 27, 2015 10-Q 2015-07-30
Q1 2015 $1.85B +$195M +11.8% Mar 28, 2015 10-Q 2015-04-30
Q4 2014 $1.87B +$238M +14.6% Dec 27, 2014 10-K 2016-02-12
Q3 2014 $1.84B +$199M +12.1% Sep 27, 2014 10-Q 2014-10-30
Q2 2014 $1.86B +$242M +14.9% Jun 28, 2014 10-Q 2014-08-07
Q1 2014 $1.65B +$48M +2.99% Mar 29, 2014 10-Q 2014-04-30
Q4 2013 $1.63B +$46.4M +2.93% Dec 28, 2013 10-K 2015-02-17
Q3 2013 $1.64B +$76.1M +4.86% Sep 28, 2013 10-Q 2013-10-30
Q2 2013 $1.62B +$75.5M +4.89% Jun 29, 2013 10-Q 2013-07-31
Q1 2013 $1.6B +$48.5M +3.12% Mar 30, 2013 10-Q 2013-05-08
Q4 2012 $1.59B +$28M +1.8% Dec 29, 2012 10-K 2014-02-25
Q3 2012 $1.57B -$17.8M -1.12% Sep 29, 2012 10-Q 2012-11-01
Q2 2012 $1.55B -$159M -9.34% Jun 30, 2012 10-Q 2012-08-07
Q1 2012 $1.56B -$189M -10.8% Mar 31, 2012 10-Q 2012-05-04
Q4 2011 $1.56B -$175M -10.1% Dec 31, 2011 10-K 2013-02-27
Q3 2011 $1.59B -$495M -23.8% Sep 24, 2011 10-Q 2011-11-02
Q2 2011 $1.71B -$451M -20.9% Jun 25, 2011 10-Q 2011-08-03
Q1 2011 $1.74B Mar 26, 2011 10-Q 2011-05-04
Q4 2010 $1.73B Dec 25, 2010 10-K 2012-02-27
Q3 2010 $2.08B Sep 25, 2010 10-Q 2010-11-04
Q2 2010 $2.16B Jun 26, 2010 10-Q 2010-08-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.